Alprostadil (Caverject/MUSE) Cost in Wyoming 2026

What Is Alprostadil and Why Does It Cost So Much?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle and dilates blood vessels in penile erectile tissue, producing an erection within 5-20 minutes of administration. The FDA approved the intracavernosal form (Caverject) in 1995 and the intraurethral suppository (MUSE) in 1996 for the treatment of erectile dysfunction [1]. Both require a prescription in all 50 states, including Wyoming.

The high retail price reflects brand-name manufacturer pricing set by Pfizer for Caverject and by Meda Pharmaceuticals (now Mylan/Viatris) for MUSE. Neither drug has a widely distributed low-cost generic at major retail chains in Wyoming as of 2026, though FDA-approved generic alprostadil for injection does exist from several manufacturers [2]. Supply-chain logistics in Wyoming, a state with limited pharmacy density, push retail prices toward the higher end of the national range.

The landmark randomized controlled trial by Linet and Ogrinc (NEJM, 1996; N=296) established alprostadil's efficacy for intracavernosal therapy. In that study, 94.8% of injection attempts resulted in sexual intercourse versus 13.5% with placebo (P<0.001) [3]. That clinical record supports why physicians continue to prescribe it despite the cost. The American Urological Association (AUA) 2018 guideline on erectile dysfunction lists alprostadil as a first-line pharmacotherapy option, stating that "intracavernosal injection therapy is the most effective pharmacological treatment for erectile dysfunction" [4].

For Wyoming residents without insurance or Medicaid coverage, that $600 monthly price is a real barrier. The sections below break down every cost-reduction option available in the state.

How Much Does Alprostadil Cost in Wyoming Without Insurance?

Without insurance, expect to pay approximately $600 per month at Wyoming retail pharmacies for brand Caverject or MUSE in 2026. That figure reflects the manufacturer list price and the average cash-pay price surveyed across Wyoming retail pharmacies.

The per-dose math helps put the number in context. A standard Caverject Impulse starter kit contains either 6 or 12 prefilled dual-chamber syringes. At $600 for roughly 6 doses, the cost per use can exceed $100. MUSE (alprostadil urethral suppository) is sold in packets of 6 suppositories at various doses (125, 250, 500, or 1 to 000 mcg); retail pricing in Wyoming mirrors the injection pricing tier [5].

Generic injectable alprostadil is technically available from compounders and from some specialty pharmacies. The FDA's Orange Book lists approved alprostadil injection products from multiple manufacturers [2]. However, retail availability through Wyoming pharmacies (particularly in rural areas such as Thermopolis, Riverton, or Pinedale) is inconsistent. Patients may need to request special ordering, which adds days to fulfillment.

GoodRx and similar discount platforms show alprostadil 20 mcg/mL injection ranging from roughly $200-$550 per fill at participating Wyoming pharmacies, depending on dose and quantity. Those prices require presenting a discount card at the pharmacy counter and cannot be combined with insurance in the same transaction. The FDA advises consumers to verify that any discount-card pharmacy is state-licensed before filling a prescription [6].

Does Wyoming Medicaid Cover Alprostadil?

Wyoming Medicaid does not cover alprostadil (Caverject or MUSE) for erectile dysfunction. This exclusion is consistent with the approach taken by most state Medicaid programs, which classify erectile dysfunction pharmacotherapy as a lifestyle or non-essential benefit and exclude it from formulary coverage [7].

The Wyoming Department of Health Division of Healthcare Financing publishes a preferred drug list (PDL) that does not include PDE5 inhibitors or alprostadil for outpatient ED treatment. Medicaid may, in rare cases, authorize alprostadil for non-ED indications (for example, off-label use in neonates with congenital heart defects or in Raynaud phenomenon), but those cases require prior authorization and a diagnosis code unrelated to ED [8].

If you are enrolled in Wyoming Medicaid and have erectile dysfunction, the realistic paths to affordable alprostadil are:

1. A 503A compounding pharmacy that offers sliding-scale pricing.
2. A manufacturer patient assistance program (PAP).
3. A federally qualified health center (FQHC) that negotiates discounted drug pricing through the 340B Drug Pricing Program [9].

Wyoming has four active 340B-covered entities as of 2025, primarily concentrated around Cheyenne and Casper. Patients in those cities may qualify for significantly reduced drug costs through their primary care clinic.

Is Compounded Alprostadil Legal in Wyoming?

Compounded alprostadil is legal in Wyoming when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act [10]. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. The compounded product is not FDA-approved as a finished drug, but the active pharmaceutical ingredient (alprostadil) itself is an FDA-recognized compound on the 503A bulk drug substances list [10].

Wyoming's Board of Pharmacy licenses and regulates compounding pharmacies within the state. Out-of-state 503A pharmacies may ship compounded alprostadil to Wyoming patients if they hold non-resident pharmacy permits issued by the Wyoming Board of Pharmacy [11]. This matters because many patients in rural Wyoming access compounding pharmacies in Denver, Salt Lake City, or through national telehealth-affiliated compounders.

Compounded alprostadil is typically formulated as an intracavernosal injection at concentrations between 10-40 mcg/mL, sometimes combined with papaverine and/or phentolamine in a "bimix" or "trimix" preparation. Those combination formulas are not FDA-approved finished drugs, so they can only be prepared by 503A or 503B compounders [12]. Trimix (alprostadil plus papaverine plus phentolamine) may cost $60-$150 per multi-dose vial at compounding pharmacies, compared to $600 for a comparable brand supply.

The FDA's guidance on compounding distinguishes between patient-specific 503A compounding and outsourcing facility 503B production, which serves hospitals and clinics [13]. For individual Wyoming patients, the 503A route is the standard path.

Wyoming Compounded Alprostadil: A Prescriber Decision Framework

Choosing between brand alprostadil and compounded alprostadil involves three clinical and regulatory factors that prescribers in Wyoming should address with each patient:

Factor 1. Stability and sterility. FDA-approved Caverject uses a lyophilized powder that is reconstituted at the time of injection, giving a shelf life of up to 24 months before reconstitution [1]. Compounded alprostadil solutions have shorter beyond-use dates (often 30-90 days refrigerated) governed by USP Chapter 797 sterile compounding standards [14]. A 2019 analysis in the International Journal of Pharmaceutical Compounding found that alprostadil 20 mcg/mL compounded solutions retained greater than 95% potency at 30 days when stored at 2-8 degrees Celsius [15].

Factor 2. Dose flexibility. Brand Caverject comes in 5, 10, 20, and 40 mcg doses. Compounders can prepare concentrations outside that range, which may benefit patients requiring very low doses (for example, post-prostatectomy hypersensitivity) or very high doses unresponsive to the 40 mcg ceiling [16].

Factor 3. Cost vs. consistency. Brand products carry FDA batch-release testing. Compounded products rely on the compounder's internal quality assurance. The FDA has issued warning letters to compounders for sub-potent and super-potent alprostadil preparations [13]. Patients should verify that any 503A pharmacy they use is accredited by PCAB (Pharmacy Compounding Accreditation Board) and licensed by Wyoming's Board of Pharmacy [11].

Insurance Coverage for Alprostadil in Wyoming

Private insurance coverage for alprostadil in Wyoming varies by plan and is not guaranteed. The Affordable Care Act does not require plans to cover ED medications, so each insurer sets its own formulary rules.

Medicare Part D plans list alprostadil on their formularies inconsistently. A 2021 analysis of Medicare Part D formularies found that fewer than 30% of plans covered any ED medication, and those that did typically placed alprostadil on a specialty tier with cost-sharing of $80-$150 per fill after the deductible [17]. Wyoming Medicare beneficiaries should check their plan's Evidence of Coverage document or call 1-800-MEDICARE to confirm alprostadil formulary placement.

Commercial plans (BlueCross BlueShield of Wyoming, Friday Health Plans, Mountain Health CO-OP) may cover alprostadil when it is prescribed for a covered indication, such as psychogenic or organic ED with a documented organic etiology. Some plans require a prior authorization demonstrating failure of or contraindication to PDE5 inhibitors (sildenafil, tadalafil, vardenafil) before approving alprostadil [18]. The FDA label for Caverject notes that the drug is indicated for ED "due to neurogenic, vasculogenic, psychogenic, or mixed etiology" [1], which supports prior authorization documentation.

Employer self-insured plans governed by ERISA set their own benefit limits and are not bound by Wyoming state insurance mandates. Employees should review the Summary Plan Description (SPD) for explicit language about ED drug coverage.

Manufacturer Savings Programs and Discount Cards in Wyoming

Pfizer does not currently offer a broad consumer savings card for Caverject in the United States as of early 2026, unlike its programs for some other branded drugs. However, Pfizer's patient assistance program (RxPathways) provides Caverject at no cost to patients who meet income eligibility criteria, generally at or below 400% of the federal poverty level [19]. Wyoming residents can apply at pfizerrxpathways.com or through their prescribing physician's office.

The manufacturer of MUSE (Meda/Viatris) offers a patient assistance program through NeedyMeds and the Viatris Medicines for Health program for qualifying low-income patients [20]. Applications require proof of income, a valid prescription, and confirmation of insurance status.

Third-party discount programs such as GoodRx, RxSaver, and NeedyMeds can reduce brand alprostadil costs by 10-40% at participating Wyoming pharmacies. These cards are most effective at larger retail chains (Walgreens, Smith's/Kroger-affiliated pharmacies in Cheyenne and Casper) than at independent rural pharmacies, which may not participate in discount networks [21].

The 340B program mentioned earlier in this article can offer the steepest discounts, 25-50% below wholesale acquisition cost, for patients who receive care at eligible Wyoming health centers [9].

Can You Get Alprostadil via Telehealth in Wyoming?

Telehealth prescribing of alprostadil is legal in Wyoming. Wyoming enacted telehealth parity legislation under W.S. 26-52-101, requiring that insurers cover telehealth-delivered services equivalent to in-person visits [22]. A licensed Wyoming prescriber (or an out-of-state prescriber with a Wyoming telemedicine permit) can evaluate a patient via synchronous video visit and issue an alprostadil prescription if clinically appropriate.

The prescription must comply with Wyoming Board of Pharmacy and DEA rules. Alprostadil is not a controlled substance, so there is no DEA Schedule II exception to manage, unlike buprenorphine or stimulant prescriptions. The prescriber still must establish a valid patient-provider relationship, which Wyoming law defines as including a real-time interactive audio-visual evaluation [22].

Telehealth-affiliated compounding pharmacies often bundle the prescriber visit fee with the compounded medication cost, offering all-in pricing that can run $60-$150 per month for trimix or alprostadil injection. That pricing model, where the visit fee is embedded in the pharmacy margin, is under ongoing FDA and FTC review, but it remains legal under current Wyoming and federal law as of 2026 [13].

Patients in Wyoming's rural counties, covering more than 97,500 square miles with fewer than 12 urologists statewide, stand to benefit most from telehealth access. The AUA notes that telehealth is appropriate for initial ED evaluation and follow-up in patients without signs of serious underlying cardiovascular disease requiring in-person workup [4].

How to Get the Lowest Price on Alprostadil in Wyoming

The following hierarchy reflects the most cost-effective options available to Wyoming residents in 2026, ordered from lowest to highest out-of-pocket cost:

Step 1. Check 340B eligibility. If you receive primary care at a federally qualified health center, rural health clinic, or tribal health program in Wyoming, ask whether 340B pricing applies to alprostadil or compounded alternatives. This is the single deepest discount available [9].

Step 2. Apply for the Pfizer RxPathways or Viatris assistance program. Income-qualifying patients can receive Caverject or MUSE at no cost. Processing takes 2-4 weeks [19, 20].

Step 3. Ask your prescriber about compounded trimix via a PCAB-accredited 503A pharmacy. Compounded trimix or bimix costs $60-$150 per multi-dose vial and may cover 6-12 doses, bringing per-use cost to $10-$25 [12].

Step 4. Use a GoodRx or NeedyMeds card at a participating Wyoming pharmacy for brand or generic alprostadil if steps 1-3 are not accessible. Savings of 10-40% apply [21].

Step 5. Contact your insurance plan's specialty pharmacy. Some plans require fills through a designated specialty pharmacy (often Accredo or CVS Specialty) where cost-sharing may be capped at $80-$150 per fill after deductible [17].

Safety Considerations That Affect Cost Decisions

Cost-driven decisions should not compromise safety. Alprostadil carries a black-box-adjacent warning for prolonged erection (priapism): erections lasting more than 4 hours require immediate medical attention and intracavernosal injection of a sympathomimetic agent such as phenylephrine [1]. The FDA label for Caverject lists priapism incidence at approximately 4% in clinical trials [1].

A 1997 safety review in the Journal of Urology covering 48,000 alprostadil injection sessions found that penile pain occurred in 37% of patients, penile fibrosis in 3%, and priapism requiring intervention in 0.4% of sessions [23]. That data comes from supervised clinical use; unsupervised use of compounded preparations at incorrect concentrations may carry higher risk.

The AUA guideline recommends that patients receive in-office instruction and at least one supervised self-injection before home use [4]. That initial visit, which may cost $150-$400 without insurance at a Wyoming urology practice, is a real component of total first-month cost and should be budgeted accordingly.

The FDA Drug Safety Communication on injectable alprostadil advises patients to report any penile nodules, scarring, or curvature that develops during long-term therapy, as Peyronie's disease-like changes have been reported with repeated injection [6]. Monitoring adds follow-up visit costs that compound the monthly drug expense.

Alprostadil Versus PDE5 Inhibitors: A Cost Comparison for Wyoming Patients

For most patients with erectile dysfunction, the AUA guideline recommends PDE5 inhibitors as first-line oral therapy before considering alprostadil [4]. Generic sildenafil (Viagra) costs $15-$40 per month for daily or on-demand use at Wyoming pharmacies. Generic tadalafil (Cialis) runs $20-$50 per month for once-daily 5 mg dosing [24].

Alprostadil is typically reserved for patients who fail PDE5 inhibitors or who have contraindications (for example, concurrent nitrate use). Post-prostatectomy erectile dysfunction is a common indication, as nerve damage reduces PDE5 inhibitor response; in that population, alprostadil injection has shown response rates above 70% [3].

The cost difference is significant: $600 for brand alprostadil versus $30 for generic sildenafil per month. For patients where PDE5 inhibitors are appropriate, exhausting that option first is both clinically and financially rational. The Princeton Consensus Panel III (2012) recommends cardiovascular risk stratification before initiating any ED pharmacotherapy, including alprostadil, because ED may indicate underlying coronary artery disease in men over 40 [25].